Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Ariad Pharmaceuticals ( ARIA)

ASCO presentation: Six-month, follow-up data from the pivotal phase III study of ponatinib in chronic myelogenous leukemia.

What we already know: Results from the first three months of the ponatinib PACE study were presented last December.

Key questions: Investors will be looking for six-month response rates to be higher than what was seen last December.

If you liked this article you might like

Insider Trading Alert - SUMR, CVO And ARQL Traded By Insiders

Insider Trading Alert - ARQL, MTSC And PFNX Traded By Insiders

Insider Trading Alert - SAVE, ARQL And THST Traded By Insiders

Insider Trading Alert - ORM, OLBK And ARQL Traded By Insiders

Insider Trading Alert - TIPT, RDNT And ARQL Traded By Insiders